版本:
中国

BRIEF-IDMC starts interim analysis of Mesoblast's phase 3 heart failure trial

March 31 Mesoblast Ltd:

* Independent Data Monitoring Committee initiates process for interim analysis of Mesoblast’S phase 3 chronic heart failure trial

* Says interim analysis dataset has been locked and will be analyzed and reviewed by trial's independent statisticians

* Mesoblast Ltd - throughout review process, co to remain blinded to individual treatment allocation as well as grouped safety and efficacy data

* Mesoblast Ltd - IDMC will review and interpret results of interim analysis and provide recommendations shortly Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐